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Introduction
In the last two decades, the field of environmental epidemiology has used several “-omics” 
platforms in an untargeted fashion to gain new insights into the complex relations between 
environmental pollutant exposures and human health.1 For instance, exposomics has been 
used to understand how exposure to complex mixtures of air pollution, chemicals, and 
metals affect health.2–4 Metabolomics and methylomics have been used to identify putative 
biological pathways affected by environmental exposures, as well as biological responses to 
exposures.5,6 Despite progress in understanding the health effects of and biological 
responses to complex exposures, relatively little has been done to understand how 
environmental pollutants affect complex disease phenotypes. Many environmental exposures 
– air pollution, lead, and secondhand tobacco smoke – have been associated with multiple 
diseases, but potentially informative patterns of multimorbidity have often been ignored.7–9
We propose to use the phenome as a novel approach to study the health effects of 
environmental exposures. We define the phenome as the patterns and profiles of human 
disease that individuals experience from birth to death; this includes disease diagnoses, 
continuous traits related to disease, and biological pathways underlying disease states. Thus, 
the phenome represents a continuum that spans from the biological pathways underpinning 
disease to the clinical manifestations of disease. Quantifying the patterns of multimorbidity 
associated with an environmental pollutant exposure may provide new information about the 
health effects of that exposure, as well as potential biological pathways related to an 
exposure. Here we describe how the Phenome-Wide Association Study (PheWAS) can be 
used as a tool to better understand how environmental exposures impact the multitude of 
health states that humans experience across the life course.
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PheWAS Background
In the early 2000’s, as the Human Genome Project was nearing completion, scientists were 
contemplating if phenotypes could be “sequenced” by the Human Phenome Project in an 
effort to understand how individual genes were associated with multiple phenotypes, thus 
gaining insight into pleiotropic effects of genes.10,11 In the context of studying individual 
single nucleotide polymorphisms (SNPs) or pollutant exposures, the PheWAS can be 
thought of as a reverse genome-wide association study (GWAS) (Figure 1). The GWAS 
estimates associations between thousands of SNPs and one or a few phenotypes or diseases, 
much like an environment-wide association study (EWAS) that examines the associations 
between multiple exposures and a phenotype.12 In contrast to these approaches, the PheWAS 
estimates associations of one or a few SNPs (or exposures) with hundreds or thousands of 
phenotypes or health states in order to identify patterns of multimorbidity related to a given 
gene or exposure.
Note, the terms comorbidity and multimorbidity have been used interchangeably in the 
literature with little consensus on the best definition.13 Here, we use the term multimorbidity 
and cumulative hierarchy proposed by van den Akker.
1. Simple multimorbidity, which includes causal, correlated, and coincidental 
disease co-occurrence. For example, the co-occurrence of cardiovascular disease 
and osteoarthritis is likely coincidental.
2. Associative multimorbidity implies a statistical relation between two or more 
diseases, and thus, includes causally-related and correlated diseases. For 
example, the symptoms of some micronutrient deficiencies are correlated, but 
non-causal since they are all related to the same common cause (e.g., Vitamin C 
deficiency).
3. Causal multimorbidity implies a causal relation between two or more diseases. 
For example, the co-occurrence of type 2 diabetes and diabetic retinopathy is 
causal since the former causes the latter.
The first PheWAS we are aware of examined the association between five SNPs and 776 
diseases or phenotypes in over 6,000 adults.14 They used the International Classification of 
Disease-9 (ICD-9) codes to define binary disease phenotypes (i.e., cases or controls). Many 
subsequent PheWAS adopted this model and have examined the association of SNPs with a 
range of clinical outcomes, usually derived from electronic medical records (EMRs).15 
Some studies have examined clinical biomarkers such as white blood cell counts or 
autoantibodies instead of SNPs as their primary exposure.16,17 For instance, Liao et al. 
reported associations between autoantibodies and clinical diagnoses defined by ICD-9 
codes, finding that antinuclear antibodies were associated with Sjӧgren’s/sicca syndrome.17 
Table 1 summarizes the design and results of several PheWAS studies.
We are unaware of any PheWAS examining an environmental pollutant as the exposure. 
However, Chen and VanderWeele used a PheWAS approach (referred to as an Outcome-
Wide Association Study by the authors) to examine the relations of religious service 
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attendance and prayer/meditation with 26 character strengths and psychological, mental, 
behavioral, and physical health outcomes.18,19
Phenome and PheWAS Framework
Regardless of the exposure of interest, a PheWAS begins by carefully defining the phenome 
and selecting appropriate data resources and study designs. Most PheWAS have used the 
ICD codes to identify specific clinical diseases. Other approaches to define phenotypes 
include using clinical text data from EMRs or data from large population-based studies.
18,20,21
 While prospective designs are the most robust in terms of causal inference, cross-
sectional studies could be used to generate new hypotheses.
Phenotypes can be classified using available ontologies like Phecodes or the Human 
Phenotype Ontology.22–24 Phecodes was developed to aggregate the ICD9 or ICD10 codes 
into hierarchical trait or disease-relevant groupings that can be used for biomedical research.
23
 The Human Phenotype Ontology also uses hierarchical groupings, but they are based on 
phenotypic abnormalities encountered in human disease and not billing codes.22,24 It is 
important to note that these ontologies use binary classifications of the phenotype (e.g., 
disease vs. no disease). However, in many epidemiologic studies, outcomes are measured as 
continuous traits (e.g., blood pressure), that can also be characterized as clinically vs. non-
clinically significant (e.g., hypertension). Thus, continuous traits are important to study 
because they may detect earlier manifestations of disease that clinical diagnosis would 
otherwise miss and provide a relative ranking of the outcomes while enhancing statistical 
power.
Here we expand the scope of the phenome beyond clinical or disease diagnoses as has been 
done in previous studies. We propose that the phenome includes clinical diagnoses, 
continuous traits underlying these diagnoses, and biological pathways related to these traits 
or diagnoses. For example, individuals can be diagnosed as obese or normal weight based on 
their body mass index (BMI), which in turn is a continuous trait that is used to assess an 
individual’s adiposity. Biological pathways related to the development or maintenance of 
obesity include hormones produced by adipose tissue (e.g., adipocytokines).
Clinical Data
Many PheWAS take advantage of EMRs that include the ICD codes. These types of data 
could be used to examine associations between environmental exposures and clinical disease 
diagnoses. The ICD-9 coding system contains a wide spectrum of phenotypes, including 
over 17,000 disease codes grouped in a multi-level hierarchy.25,26 Because the ICD coding 
system was designed primarily for billing and administrative functions, customized 
groupings of ICD codes are needed to approximate clinical disease phenotypes for a 
PheWAS. For example, similar ICD codes like primary tuberculosis and late effects of 
tuberculosis should be combined, but similar codes representing distinctly different diseases, 
like Type 2 and Type 2 diabetes, should be separated.14 Finally, another approach that may 
capture more detailed information, is to use clinical text, examination, or laboratory data 
from EMRs instead of ICD-9 codes to define the phenome. For instance, Hebbring and 
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colleagues used EMR data to develop a text-based phenome by documenting clinical text 
and reducing it to clinically relevant phenotypes.20
Two limitations of using administrative databases containing ICD codes or EMRs for a 
PheWAS are worth noting. First, these databases have a limited number of environmental 
pollutant exposures available. Ambient air pollution, temperature, or other built environment 
factors could be assessed by linking participant addresses to publicly available datasets. In 
addition, for some sub-populations, individual-level environmental exposure data might be 
available (e.g., childhood blood lead concentrations). Second, outcome misclassification 
may arise when relying on the ICD codes or EMRs, which would result in reduced statistical 
power, assuming non-differential misclassification. For instance, the ICD codes are specific, 
but not sensitive, at classifying cardiovascular and chronic kidney disease.27,28
Large Datasets with Detailed Phenotyping
Large datasets, such as the National Health and Nutrition Examination Surveys (NHANES), 
conduct biomonitoring for a wide range of ubiquitous environmental chemicals and assess a 
large and diverse set of phenotypes.29 A number of disease diagnoses, continuous 
phenotypes, and underlying biological pathway data have been systematically assessed using 
questionnaires, direct assessments, and biomarkers in the NHANES (Table 1). These include 
anthropometry, oral health, metabolic and endocrine biomarkers, neurodevelopment, 
respiratory health, allergies, and questionnaire data related to numerous disease diagnoses.30 
Other data resources that would have detailed phenotype information include ongoing 
prospective cohort studies of adults or children, including the National Institutes of Health 
Environmental Determinants of Child Health Outcomes (ECHO) Study.31–33
Several limitations to using these types of datasets for PheWAS are worth noting. First, some 
databases, like the NHANES, are cross-sectional, thus, creating temporal ambiguity between 
exposure and phenotypes. Second, cross-sectional data could only be used to study prevalent 
conditions. Third, some of these databases would have low statistical power for rare 
conditions (e.g., specific forms of cancer). Finally, some self-reported diagnoses may not be 
completely accurate, but in some cases they could be augmented by clinical examination 
data (e.g., measured blood pressure instead of self-reported diagnosis of hypertension).
Analyzing and Interpreting Phenome Data
To facilitate analysis and interpretation, phenotypic information could be hierarchically 
classified based on available ontologies or characterized in coarser groupings based on organ 
systems (e.g., cardiovascular vs. metabolism).22–24 These classes could serve as a 
“backbone” that can be used to organize the array of assessed phenotypes and facilitate 
interpretation of associations between a given pollutant and multiple phenotypes. This is 
akin to chromosomes in a GWAS or groups of exposure (e.g., metals, phthalates, pesticides, 
etc.) in a EWAS. For example, using the Human Phenotype Ontology, Type 2 diabetes and 
hypothyroidism are both classified as endocrine system abnormalities, but further 
distinctions can be made based on the specific endocrine organs affected.
Some additional considerations should be made when curating phenotype data. First, the 
same phenotype is often measured with multiple measures and some of these measures are 
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highly correlated (e.g., different measures of adiposity).34 Thus, it may only be necessary to 
include one of these measures depending on the degree of correlation and goal of the 
specific PheWAS. Additionally, some diseases or phenotypes with similar etiologies may 
need to be distinguished based on lifestage (e.g., Type 2 diabetes vs. gestational diabetes).
When analyzing phenome data, the entire phenome could be examined or a specific class of 
the phenome. This latter approach could be used when there is limited phenotype data 
available for some classes or there is an a priori hypothesis about the potential effects of an 
exposure. For instance, one could conduct a PheWAS to examine the association between a 
potentially immunotoxic compound and immune-related outcomes.
Interpreting PheWAS results can be facilitated by examining patterns of associations 
between the exposure and outcomes within and across phenotype classes. Using ontologies 
and the observed pattern of exposure-associated multimorbidity, decisions about the causal 
or non-causal nature of the relations between an exposure and outcome(s) can be made. For 
instance, observing associations between an exposure and multiple cardiovascular endpoints 
might suggest a common biological mechanism of action for that agent. However, an 
exposure associated with two biologically unrelated diseases could suggest a non-causal 
multimorbidity.
Like GWAS and EWAS, replication is necessary for PheWAS to ensure that significant 
associations are not spurious. Replication studies could be conducted on a portion of the 
original data (e.g. 20%) or another dataset with similar features of the original data set.
Advantages of PheWAS
The PheWAS has several potential applications to the field of environmental epidemiology 
that could help enhance our knowledge about specific pollutants and biological pathways 
related to these pollutants.
First, the PheWAS can be used as a tool to generate new hypotheses about specific exposures 
and human health. By examining a multitude of phenotypes, the PheWAS can efficiently 
provide information for exposures with little or no data about their potential health effects. 
Thus, the PheWAS can be used to guide the development of more targeted studies in cases 
where human health data are lacking. For instance, this can be quite important as some 
chemicals are phased out of commerce and industry, and replaced with compounds that have 
little or no toxicity data available (e.g., phthalate and perfluoroalkyl substance 
replacements).
Second, the PheWAS can improve our understanding of environmental exposures and related 
biological pathways by examining patterns of phenotypes associated with a single exposure. 
Because many disease processes are related to common biological pathways, exposure-
induced effects on a given pathway or set of pathways could produce ‘environmentally 
pleiotropic’ effects. Thus, the PheWAS can provide evidence that an exposure alters specific 
biological pathways if that exposure is associated with multiple diseases or phenotypes 
related to that pathway. For example, active and secondhand tobacco smoke exposures are 
associated with the metabolic syndrome, a constellation of symptoms that includes excess 
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central adiposity, hypertension, dyslipidemia, impaired glucose tolerance, and insulin 
resistance.35–37 Thus, tobacco smoke exposure may cause these effects by altering 
inflammatory, epithelial, and vascular pathways that are related to features of the metabolic 
syndrome.
Finally, the PheWAS can be used to generate new hypotheses about established toxicants 
(e.g., lead or tobacco smoke exposure) in an effort to more comprehensively assess their 
potential health effects. Novel exposure-phenotype associations would be difficult to identify 
when studying individual outcomes one-at-a-time. Exposure-associated patterns of 
multimorbidity may occur when an exposure affects a biological pathway related to multiple 
diseases or phenotypes. For instance, children often have multiple neurodevelopmental 
disorders (e.g., both attention-deficit/hyperactivity disorder and conduct disorder), and this 
pattern of multimorbidity may be related to perturbations of the same biological pathway(s).
38
 Indeed, some environmental neurotoxicants, like lead, have been associated with both 
attention-deficit/hyperactivity disorder and conduct disorder.39,40 Moreover, the PheWAS 
approach avoids selective reporting and publication bias by describing an exposure’s 
association with all outcomes, even those that are null.
Challenges to Conducting PheWAS
Despite the advantages of PheWAS, there are several challenges in implementing them 
related to multiple testing, data availability, phenotyping quality, sample size, analyzing and 
characterizing phenotypes, the dynamic nature of exposure and outcomes, and controlling 
for confounding.
As is the case with all high dimensional data, there is a risk of false positives when 
examining associations between a single exposure and hundreds or thousands of phenotypes. 
For instance, there are over 17,000 potential ICD-9 codes and >155,000 ICD-10 codes.41 
Traditionally, null hypothesis testing with correction for multiple comparisons is used to 
“filter” out potentially false positive results using Bonferroni correction, family-wise error 
rates correction, or false discovery rate control.42 Alternatively, statistical techniques can be 
used to reduce the dimensionality of the phenotype data (e.g., principal components). 
However, these statistical techniques could produce components or clusters that are difficult 
to interpret, not related to the exposure, or be method-dependent.43
Another potential concern when conducting a PheWAS is the availability and quality of the 
phenotyping data. One cannot acquire phenotype data in a similar to that used for other “-
omics” technologies. In genomics, epigenomics, and metabolomics, thousands of features 
can be interrogated simultaneously on a single platform (e.g., sequencing, microarrays, or 
mass-spectrometry based approaches). Despite their high cost on a per-assay level, these 
platforms are quite efficient on a per-feature level. However, these platforms do not exist for 
phenotyping, thus making it more challenging to conduct a PheWAS.
PheWAS require studies that collectively have a large sample size and common protocol for 
phenotype assessment. Examples include EMR databases, the NHANES, or extraordinary 
cohorts such as the Nurses’ Health Study or ECHO.44,45 While smaller cohort studies with 
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detailed and research-quality phenotype measures could be used to conduct a PheWAS, they 
may assess a small number of diseases or phenotypes, have limited statistical power in the 
face of multiple testing correction, and be unable to examine rare diseases. Larger studies 
using EMRs will have access to a fuller spectrum of clinical disorders and sufficient 
statistical power to analyze most rare diseases, but there may be misclassification of some 
outcomes and inability to examine biological pathways. A hybrid approach could be 
employed where larger studies are used for discovery and smaller studies for replication and 
interrogation of specific biological pathways.
The dynamic nature of exposure must be considered in PheWAS. In genetic studies 
employing PheWAS, the exposure (i.e., single nucleotide polymorphisms) is static across the 
lifespan. However, in the environmental PheWAS, exposures change across the lifespan and 
there may be discrete periods of vulnerability for some exposures that differ with respect to 
phenotype.46 There are at least three strategies to deal with this. First, PheWAS studies could 
examine exposures exhibiting less within-person variation (e.g., persistent pollutants) since 
exposure misclassification would be reduced relative to exposures with more within-person 
variation (e.g., bisphenol A).47 Second, cumulative measures of exposure representing 
specific periods of life could be used (e.g., deciduous tooth biomarkers).48 Third, exposure 
during discrete periods of life could be examined (e.g., early childhood or concurrent), 
acknowledging that they may not be relevant for some health outcomes
In addition, phenotypes change over time. For example, some phenotypes might not 
manifest until a specific age (e.g., pubertal development) or some diseases might resolve 
(e.g., eczema). Moreover, the development of one disease may increase the risk of another 
disease or phenotype. For instance, adults with type 2 diabetes have impairments in 
executive functions, which might arise because of diabetes-induced damage to brain 
microvasculature.49 The possibility of a chain of risk makes it necessary to consider the 
longitudinal nature of health trajectories and comorbidities when conducting a PheWAS 
study.
Finally, in any observational study, proper confounding control requires adjustment for 
predictors of both exposure and outcome, while not adjusting for causal intermediates or 
colliders.50 As Vanderweele points out, this can be relatively easily accomplished in a 
PheWAS since only one exposure is being considered and it is sufficient to adjust only for 
predictors of exposure, even if not all these variables predict the outcome.19 This is in 
contrast to exposomic studies, which consider a multitude of exposures, some of which are 
correlated to one another due to shared exposure sources (e.g., phthalates),51 or may be 
related to each other through various causal pathways (e.g., built environment factors 
affecting activity patterns). Additionally, measuring confounder data prospectively with 
respect to exposure mitigates the risk of adjusting for colliders or intermediates. 
Investigators could minimize bias from confounding and adjustment for colliders or 
intermediates by carefully select confounding variables using directed acyclic graphs or 
single world intervention graphs.52,53
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Future Directions
The time has come for the field of environmental epidemiology to embrace the phenome 
given the increasing emphasis on studying complex exposures and biological pathways 
using different “-omics” methods. As a first step, we propose that PheWAS studies of 
relatively well-characterized exposures be conducted to demonstrate the utility of these 
studies and identify hurdles to implementing them. This will require the identification and 
curation of data resources that have assessed at least one environmental exposure and the 
phenome. Potential resources include the NHANES, large cohorts studies (e.g., Nurse’s 
Health Study),32 or EMR databases. More specialized resources focused on distinct life 
stages (i.e., children’s health) could pool data from existing National Institute of 
Environmental Health Sciences funded Children’s Environmental Health Centers or the 
National Institute of Health funded ECHO Study.31,54
Several issues bear additional reflection as we incorporate the PheWAS into our “-omics” 
toolbox. First, it will be important to consider how to incorporate life course approaches into 
studies of the phenome given that many diseases and phenotypes have early life origins and 
are dynamic in nature.55,56 Second, there will be the need to consider how to combine and 
analyze different forms of highly dimensional data (e.g., the exposome and phenome). 
Already, there have been calls for more integration of different types of molecular data, but 
this call could be extended to include the exposome and phenome as well.57 Finally, and 
related to this, it will be necessary to examine the relations between environmental pollutant 
mixtures and the phenome.58 Ultimately, studying the relations between complex exposures, 
biological pathways, and the phenome across the lifespan may lead to new insights about the 
contribution of environmental exposures to human health and wellbeing.
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Highlights
• Epidemiology has not considered whether pollutants have pleiotropic effects.
• The phenome is the patterns/profiles of disease experienced from birth to 
death.
• Phenome Wide Association Studies (PheWAS) examine a pollutant and all 
phenotypes.
• Using PheWAS could improve our understanding of the health effects of 
pollutants.
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Figure 1: 
Graphical depiction of a GWAS (A), genotype PheWAS (B), EWAS (C), and exposure 
PheWAS (D)
*-GWAS: Genome Wide Association Study, PheWAS: Phenome Wide Association Study, 
EWAS: Exposome Wide Association Study.
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Table 1:
Selected examples of prior phenome wide association studies
Paper N Exposure Phenome Number of phenotypes Results
Denny et al. 
2010
6,005 SNPs (5) previously 
linked to atrial 
fibrillation, Crohn’s 
disease, carotid artery 
stenosis, coronary artery 
disease, multiple 
sclerosis, systemic lupus 
erythematosus and 
rheumatoid arthritis
ICD9 codes 776 Four of the known SNP-
disease associations were 
replicated and 19 new 
associations were identified
Polimanti et 
al. 2016
26,394 SNPs (8) in CHRNA3–
CHRNA5 locus, 
ADH1B, and ALDH2
Large cohort database 360 Replicated findings that 
these SNPs are associated 
with drinking and smoking 
behaviors as well as novel 
findings that these SNPs 
were associated with 
psychological traits
Hebbring et 
al. 2015
4,235 SNPs (5) previously 
linked to multiple 
sclerosis, ankylosing 
spondylitis, triglyceride 
levels, atrial fibrillation 
and age-related macular 
degeneration
Clinical text data from 
EMRs
23,384 Replicated findings and 
demonstrated that raw text 
data can be used to define a 
phenome
Warner and 
Alterovitz 
2012
36,095 White blood cell counts ICD9 codes 5,675 Peak WBC counts between 
15–45 K/μl were associated 
with Clostridium difficile 
and bacterial sepsis
Liao et al. 
2013
1,290 cases
1,236 controls
Autoantibodies (anti-
citrullinated protein 
antibodies, antinuclear 
antibodies, antitissue 
transglutaminase 
antibodies, antithyroid 
peroxidase)
ICD9 codes 512 in cases
698 in controls
In cases, the presence of 
antinuclear antibodies 
(ANA) was associated with 
Sjӧgren’s/sicca syndrome
In controls, higher ANA 
was associated with chronic 
nonalcoholic liver disease
In both cases and controls, 
anti-thyroid peroxidase 
antibodies was associated 
with hypothyroidism
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Table 2:
Health dimensions assessed in NHANES, corresponding measurements, and measurement method(s)a
Health Dimension NHANES Measurements Method Of Measurement
General Health
Current Health Status Questionnaire
Physician Exam Physical Examination
Medical Conditions Questionnaire
Physical Health
Physical Activity and Physical Fitness Questionnaire
Physical Activity Monitor Physical Examination
Physical Functioning Questionnaire
Physical Functioning-Timed Walks Physical Examination
Isokinetic Knee Extensors Strength Physical Examination
Mental Health
Attention Deficit Hyperactivity Disorder Questionnaire
Anxiety Questionnaire
Conduct Disorders Questionnaire
Depression Questionnaire
Eating Disorders Questionnaire
Elimination Disorders Questionnaire
Panic Disorder Questionnaire
Depression Questionnaire
Cognitive Functioning
Cognitive Functioning Examination
Body Composition/Bone Health
Anthropometry Measurements Physical Examination
Bioelectric Impedance Analysis Physical Examination
Dual Energy X-Ray Absorptiometry Physical Examination
Body Composition Physical Examination
Bone Density-Hip and Spine Physical Examination
Vertebral Fracture Assessment Physical Examination
Weight History Questionnaire
Osteoporosis Questionnaire
Bone Alkaline Phosphatase Laboratory Measurement
N-telopeptide (NTX) Laboratory Measurement
Muscular Health
Grip Strength Test Physical Examination
Muscle Pain Questionnaire
Creatinine Kinase Laboratory Measurement
Creatinine Phosphokinase Laboratory Measurement
Creatinine Laboratory Measurement
Dermatologic Health
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Health Dimension NHANES Measurements Method Of Measurement
Dermatology Questionnaire, Physical Examination
Ocular Health
Vision Questionnaire, Physical Examination
Retinal Photography Physical Examination
Visual Fields Physical Examination
Oral Health
Oral Health Questionnaire
Dental Fluorosis Imaging Physical Examination
Auditory Health
Audiometry Physical Examination
Hearing/Audiometry Questionnaire
Respiratory Health
Respiratory Health and Disease Questionnaire
Exhaled Nitric Oxide Laboratory Measurement
Spirometry Laboratory Measurement
Cardiovascular Health
Cardiovascular Disease Questionnaire
Cardiovascular Fitness Physical Examination
Blood Pressure Questionnaire, Physical Examination
Peripheral Vascular Disease Physical Examination
Fibrinogen Laboratory Measurement
Thyroid Function
Thyroid Hormones Laboratory Measurement
Parathyroid Hormone Laboratory Measurement
Gastrointestinal Health
Bowel Health Questionnaire
Celiac Disease Laboratory Measurement
Renal and Urinary Health
Urology Questionnaire
Kidney Conditions Questionnaire
Urine Flow Rate Calculations Laboratory Measurement
Urine Osmolality Laboratory Measurement
Chemistry Panel Laboratory Measurement
Prostrate Conditions Questionnaire
Prostrate Health Specific Antigens Laboratory Measurement
Hepatobiliary System
Chemistry Panel Laboratory Measurement
Albumin Laboratory Measurement
C-Reactive Protein Laboratory Measurement
Reproductive Health and Gonadal Hormone Function
Reproductive Health Questionnaire
Pubertal Maturation Questionnaire
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Health Dimension NHANES Measurements Method Of Measurement
Testosterone Laboratory Measurement
Sex Hormone Binding Globulin Laboratory Measurement
Follicle Stimulating Hormone Laboratory Measurement
Luteinizing Hormone Laboratory Measurement
Immune System
Complete Blood Count Laboratory Measurement
White Blood Count Laboratory Measurement
Deoxyribonucleic Acid Laboratory Measurement
Sleep
Sleep Disorders Questionnaire
Arthritis
Arthritis Body Measures Physical Examination
Inflammatory Arthritis Pain Questionnaire
Arthritis Biomarkers Laboratory Measurement
Glucose Metabolism/Diabetes
Diabetes Questionnaire
Oral Glucose Tolerance Laboratory Measurement
Glucose Laboratory Measurement
Insulin/C-peptide Laboratory Measurement
Glycohemoglobin Laboratory Measurement
Peripheral Neuropathy Physical Examination
Dyslipidemia
Questionnaire, Laboratory
Cholesterol Measurement
High Density Lipoprotein Laboratory Measurement
Low Density Lipoprotein Laboratory Measurement
Triglycerides Laboratory Measurement
Lipoprotein(a) Laboratory Measurement
Apolipoprotein Laboratory Measurement
Allergy
Allergy Questionnaire
Immunoglobulin E-allergens Laboratory Measurement
Nutritional Biomarkers
Erythrocyte Protoporphyrin Laboratory Measurement
Ferritin Laboratory Measurement
Total Iron Binding Capacity/Transferrin 
Saturation
Laboratory Measurement
Transferrin Receptor Laboratory Measurement
Methylmalonic Acid Laboratory Measurement
Vitamin A Laboratory Measurement
Vitamin E Laboratory Measurement
Carotenoids Laboratory Measurement
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Health Dimension NHANES Measurements Method Of Measurement
Vitamin B6 Laboratory Measurement
Vitamin B12 Laboratory Measurement
Vitamin C Laboratory Measurement
Vitamin D Laboratory Measurement
Vestibular Function
Balance Questionnaire, Physical Examination
a-Some measurements are assessed using multiple modalities. For instance, diabetes can be assessed by questionnaire and laboratory-based 
measurements.
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